Christopher Turner

Christopher Turner

No open positions remaining
58 year
Health Technology
Health Services
Consumer Services

Profile

Christopher D.
Turner
worked as Head-Clinical Research at ARIAD Pharmaceuticals, Inc. from 2008 to 2014.
From 2014 to 2018, served as Vice President-Clinical Science at Celldex Therapeutics, Inc. Between 2018 and 2021, held the position of Vice President-Clinical Development at Blueprint Medicines Corp.
Formerly held roles as Director-Pediatric Neuro Oncology Outcomes at Dana-Farber Cancer Institute, Inc. and Director-Pediatric Neuro Oncology Outcomes Clinic at The Children's Hospital Corp.
From 2021 to 2026, worked as Chief Medical Officer at Nuvalent, Inc. Education includes undergraduate studies at Bowdoin College and a doctorate from the University of Rochester School of Medicine & Dentistry.

Former positions of Christopher Turner

CompaniesPositionEnd
NUVALENT, INC. Chief Tech/Sci/R&D Officer 2026-07-14
BLUEPRINT MEDICINES CORPORATION Corporate Officer/Principal 2021-02-28
CELLDEX THERAPEUTICS, INC. Corporate Officer/Principal 2018-04-30
ARIAD PHARMACEUTICALS, INC. Chief Tech/Sci/R&D Officer 2014-06-30
Corporate Officer/Principal -
See the detail of Christopher Turner's experience

Training of Christopher Turner

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

60

1st degree connections

8

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies8

Health Technology

Health Services

Consumer Services

Health Services

Health Technology

Health Technology

Consumer Services

Health Technology

  1. Stock Market
  2. Insiders
  3. Christopher Turner